(IXUS) Core MSCI Total - Overview
Etf: Developed, Emerging, Equity, Ex-US, Broad
Dividends
| Dividend Yield | 3.43% |
| Yield on Cost 5y | 4.52% |
| Yield CAGR 5y | 5.52% |
| Payout Consistency | 90.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 13.9% |
| Relative Tail Risk | 1.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.75 |
| Alpha | 24.33 |
| Character TTM | |
|---|---|
| Beta | 0.675 |
| Beta Downside | 0.641 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.75% |
| CAGR/Max DD | 1.28 |
Description: IXUS Core MSCI Total January 29, 2026
The iShares Core MSCI Total International Stock ETF (IXUS) seeks to track a free-float-adjusted, market-cap weighted index that captures the equity performance of both developed and emerging markets outside the United States. To achieve this, the fund invests at least 80 % of its assets in the index’s component securities or in securities that are “substantially identical” in economic characteristics, thereby ensuring tight tracking error while maintaining broad diversification across regions and sectors.
As of the latest quarterly filing (Q4 2025), IXUS holds approximately $48 billion in assets under management, with an expense ratio of 0.09 %. The portfolio’s top sector allocations are Financials (≈ 21 %), Consumer Staples (≈ 13 %), and Health Care (≈ 12 %). Geographically, Europe accounts for about 45 % of the net assets, Asia-Pacific (excluding Japan) ≈ 30 %, and Emerging Markets ≈ 15 %. Recent net inflows total roughly $1.2 billion for the year, reflecting continued investor appetite for diversified non-U.S. equity exposure amid mixed global growth outlooks.
For a deeper dive into IXUS’s risk-adjusted performance and how its regional exposures align with macro-economic trends, you may find ValueRay’s analytical tools useful.
What is the price of IXUS shares?
Over the past week, the price has changed by +1.21%, over one month by +4.85%, over three months by +9.66% and over the past year by +35.48%.
Is IXUS a buy, sell or hold?
What are the forecasts/targets for the IXUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 107.9 | 18.7% |
IXUS Fundamental Data Overview February 09, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 54.56b USD (54.56b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 54.56b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 54.56b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.40% (E(54.56b)/V(54.56b) * Re(8.40%) + (debt-free company))
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)